CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translational studies. CMX-2043 will be Phase 2-ready by the first quarter of 2024.
Read Press ReleaseThe research opens the doors for promising applications that can help people with neurological diseases such as Parkinson's.
Read Press ReleaseThe appointment further strengthens the company's scientific resources, including in neuronal function and synaptic transmission, which are central to Neurocentria's approach for developing novel therapies for neurodegenerative and neuropsychiatric disorders.
Read Press ReleaseGuentzel and ADHD Online partner to publish a podcast episode every day during October, providing information and support while breaking down stigmas about ADHD and mental health.
Read Press ReleaseThe National Institute of Health awards Cortechs.ai a multimillion grant to quantify microstructural changes in Alzheimer's Disease using Restriction Spectrum Imaging.
Read Press ReleaseNovel NRCT-101SR shown in previous human studies to be effective and well-tolerated with no side effects
Read Press Release